Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market 2021-2025

Global Attention Deficit Hyperactivity Disorder Drugs Market 2021-2025

Technavio has been monitoring the attention deficit hyperactivity disorder drugs market and it is poised to grow by $ 9.61 bn during 2021-2025, progressing at a CAGR of 9.06% during the forecast period. Our report on the attention deficit hyperactivity disorder drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising government support and increasing expenditure on prescription drugs. In addition, rising government support is anticipated to boost the growth of the market as well.

The attention deficit hyperactivity disorder drugs market analysis includes the product segment and geographic landscape.

Technavio's attention deficit hyperactivity disorder drugs market is segmented as below:

By Product

• Stimulants
• Non-stimulants

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies the rising prevalence of mental illnessesas one of the prime reasons driving the attention deficit hyperactivity disorder drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on attention deficit hyperactivity disorder drugs market covers the following areas:

• Attention deficit hyperactivity disorder drugs market sizing
• Attention deficit hyperactivity disorder drugs market forecast
• Attention deficit hyperactivity disorder drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading attention deficit hyperactivity disorder drugs market vendors that include Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc. Also, the attention deficit hyperactivity disorder drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., Tris Pharma Inc.